Table 1. Baseline characteristics of patients at diagnosis of lung cancer.

ICI: immune checkpoint inhibitor; T: the size and position of the tumor; N: the presence of spread into the lymph nodes

*E.g., endobronchial stent or laser treatment

Characteristics	Non-ICI	Non-ICI	ICI	ICI	P-value
Number of patients	32	100%	32	100%
Age in years, median (range)	69 (55-77)		69 (51-81)		>0.3
Female	16	50%	16	50%	>0.3
Male	16	50%	16	50%
Married or partnered	23	72%	21	66%	>0.3
Single	9	28%	11	34%
No comorbidity	11	34%	14	44%	>0.3
Cardiovascular comorbidity	11	34%	5	16%
Diabetes mellitus	10	31%	7	22%
Chronic obstructive pulmonary disease	0	0%	3	9%
Active smoker	14	44%	7	22%	0.11
Weight loss of at least 5%	15	47%	16	50%	>0.3
Squamous cell cancer	8	25%	14	44%	0.19
Non-squamous cell cancer	24	75%	18	56%
T1-2	20	63%	11	34%	0.04
T3-4	12	38%	21	66%
N0-1	8	25%	10	31%	>0.3
N2-3	24	75%	22	69%
Stage I or II	1	3%	2	6%	>0.3
Stage III	9	28%	8	25%
Stage IV	22	69%	22	69%
Liver metastases	4	13%	7	22%	>0.3
Bone metastases	5	16%	8	25%	>0.3
Brain metastases	8	25%	5	16%	>0.3
Pleural or contralateral lung metastases	8	25%	11	34%	>0.3
Curative intent in first-line	3	9%	7	22%	0.3
Any palliative care team involvement	19	59%	16	50%	>0.3
Any thoracic radiotherapy	18	56%	22	69%	>0.3
Only one line of systemic therapy	19	59%	8	25%	0.13
Two lines of systemic therapy	11	34%	15	47%
More than two lines of systemic therapy	2	6%	9	28%
Intervention during the last month*	0	0%	0	0%	>0.3
Pleurodesis or drainage (last month)	3	9%	10	31%	0.06
Death expected, therapy ceased	17	53%	15	47%	>0.3
Unexpected death, still on therapy	8	25%	8	25%
Medical records lack sufficient details regarding this parameter	7	22%	9	28%